The diameter of an abdominal aortic aneurysm (AAA) is the single most important factor in deciding whether to repair an aneurysm or to monitor it conservatively. Open surgical repair does not appear to be beneficial until the diameter of the aneurysm is >5. Elective abdominal aortic aneurysm (AAA) repair is a prophylactic procedure designed to prevent aneurysm rupture. Like any therapeutic endeavor, its success must be gauged by the safety of the procedure itself and by its long-term effectiveness in preventing rupture. It is not surprising that the earliest attempts at AAA repair were neither safe nor effective. For instance, wrapping and wiring of aneurysms, procedures developed in the first half of the 20th century, were associated with high procedural morbidity without a sufficient reduction in the risk of rupture.
Elective abdominal aortic aneurysm (AAA) repair is a prophylactic procedure designed to prevent aneurysm rupture. Like any therapeutic endeavor, its success must be gauged by the safety of the procedure itself and by its long-term effectiveness in preventing rupture. It is not surprising that the earliest attempts at AAA repair were neither safe nor effective. For instance, wrapping and wiring of aneurysms, procedures developed in the first half of the 20th century, were associated with high procedural morbidity without a sufficient reduction in the risk of rupture. 1 Even today, the morbidity and mortality of aneurysm repair can be considerable, especially in compromised patients. Although excellent outcome has been achieved in high-volume tertiary referral centers, mortality rates as high as 7% and perioperative morbidity rates of up to 50% or more persist in some communities. 2 Even higher rates of complications are observed in patients with significant cardiac, pulmonary, or renal dysfunction. 3, 4 For this reason, aneurysm repair has been reserved for select patients, weighing the risk of rupture against the morbidity and mortality of the procedure. The diameter of an aneurysm is perhaps the single most important variable predicting rupture and, as such, is the primary consideration when recommending repair or observation to patients with aneurysms. [5] [6] [7] Several randomized clinical trials have identified an AAA size of 5.5 cm as a reasonable threshold for recommending open surgical repair. Nevertheless, if a procedure with zero morbidity and uniform durability were available, all aneurysms would be treated, irrespective of size.
By contrast, the two currently available techniques for aneurysm repair-open and endovascular (EVAR)-are associated with significant operative risk and far from consistent durability. Given that the decision to repair an aneurysm in a specific patient is determined by weighing the risk of rupture against the risks of the procedure, less morbid techniques might be offered to patients with smaller aneurysms. Intuitively, EVAR should be associated with lower perioperative morbidity than open surgery. As long as the long-term durability of EVAR in preventing postrepair aneurysm rupture is low, a reduced perioperative complication rate might tip the balance in favor of repair over surveillance for small AAAs.
Studies uniformly identified lower mortality with EVAR, 8 but the two well-powered randomized clinical trials have not demonstrated such a difference. 9, 10 The randomized studies, however, included patients with larger as well as smaller aneurysms, and some data suggest that EVAR for small aneurysms is associated with extremely low procedural morbidity. 11, 12 With these concepts in mind, randomized studies were organized to determine whether benefit exists for EVAR vs observation in patients with smaller AAA.
OPEN REPAIR VS SURVEILLANCE IN SMALL AORTIC ANEURYSMS
Two prospective clinical trials have compared surveillance with open repair of 4-to 5.5-cm AAAs: the Aneurysm Detection and Management (ADAM) trial 13 and United Kingdom Small Aneurysm Trial (UKSAT). [13] [14] [15] The conclusions of the trials were similar: no benefit of early open surgical repair was conferred in patients with a small AAA (Table I ). In UKSAT, this conclusion was reached despite a statistically significant improvement in long-term survival with early open repair. This finding, however, was present at a single time point and was considered to be a result of lifestyle modification in the surgical group (eg, smoking cessation), rather than to a direct reduction in the rate of rupture. Of note, the perioperative mortality rates associated with open repair were quite high in both trials: 2.1% in ADAM and 5.4% in UKSAT. Ouriel 267
OPEN REPAIR VS EVAR IN LARGER ANEURYSMS

THE PIVOTAL STUDY OF EVAR VS SURVEILLANCE IN PATIENTS WITH SMALL AAA
The PIVOTAL trial is a prospective 70-site trial of early EVAR using the AneuRx or Talent devices (Medtronic, Santa Rosa, Calif) vs surveillance for treatment of AAAs 4-to 5-cm in diameter. Funded by Medtronic Vascular, the study and its analysis are being performed independently by the Cleveland Clinic (Table II) .
The plan calls for a 1050-patient sample size, 525 in each group, calculated on an assumed rate of the primary end points of (1) aneurysm rupture and (2) the composite outcome of AAA-related death up to 3 years. Data from the ADAM and UKSAT trials documented a 3-year event rate of 5.1% in surveilled patients with small aneurysms, linearly extrapolated to 1.7% annually. The Cleveland Clinic EVAR database 11 was used to calculate a 3-year composite event rate of 2.1%, corresponding to an annualized rate of 0.7%. These event rates corresponded to a hazard ratio of 0.42 (0.71%/1.7%) for surveillance vs EVAR in patients with small aneurysms. For power calculations, a constant hazard ratio was assumed over time; actual analyses will account for nonconstant hazard in either or both groups. Sample size calculation used a hazard ratio of 0.42, with 80% power at the 0.05 significance level, and assumed that 18% of patients would be lost to follow-up over 3 years.
Major inclusion criteria are the ability to meet all the indications for use for the endograft, age 40 to 90 years, and a low to moderate risk according to the Society for Vascular Surgery/American Association for Vascular Surgery comorbidity scoring system. 18 Eligible patients must also have a life expectancy of at least 3 years. Exclusion criteria are designed to preclude the enrollment of patients who have aneurysm anatomy not amenable to treatment with an endograft and any patients with comorbidities that would complicate repair or result in inordinate operative risk. Patients are excluded who have any planned surgical or interventional procedure Յ30 days after enrollment, a myocardial infarction without revascularization Յ6 months or with revascularization Ͻ30 days before enrollment, a known iliac aneurysm Ն3.0 cm, or a known thoracic aneurysm Ն5.0 cm.
In addition to the primary end points of rupture and AAA-related death, secondary end points include assessment of mortality in smokers vs nonsmokers, conversion to open surgical repair, successful deployment of the endograft, endograft occlusion, endoleak Յ1 year, aneurysm shrinkage or growth, quality of life, and occurrence of serious adverse events. An economic substudy will also compare medical resource usage and associated costs in the EVAR and surveillance groups.
Enrolled patients undergo randomization to early repair or surveillance. Patients in the surveillance arm of PIVOTAL are assessed at 6, 12, 18, 24, 30, and 36 months by ultrasound imaging or computed tomography. Surveillance patients will be eligible for EVAR or open repair when they become symptomatic or the AAA diameter reaches 5.5 cm or enlarges by Ն0.5 cm in 6 months or by Ն1.0 cm in a year. All patients are monitored for at least 3 years or until a primary end point is reached. As of November 2008, just over 700 patients have been enrolled in the study. The trial is expected to complete enrollment within the next year.
LOGIC INHERENT IN THE PIVOTAL STUDY DESIGN
The DREAM, EVAR-1, and a number of retrospective studies documented lower perioperative mortality rates in EVAR compared with open repair of larger aneurysms. ADAM and UKSAT demonstrated similar long-term results after open operation vs surveillance in patients with smaller aneurysms. If outcomes after EVAR are better in patients with smaller vs larger aneurysms as suggested from retrospective database analyses, 11, 12, [19] [20] [21] then survival after EVAR might actually be improved in patients with small aneurysms.
Smaller AAAs can be more favorable for EVAR as a result of suitable aortic anatomy. In one study, AAAs Ͻ5.5 cm had longer necks, less angulation, less tortuosity, and longer iliac landing zones than AAAs Ͼ5.5 cm. 20 With each 1-cm increase in diameter, anatomic suitability for EVAR decreased fivefold. Thus, some candidates for EVAR at AAA diameters of 4 to 5.5 cm might no longer be suitable when diameters are Ͼ5.5 cm and thus might be subject to the increased risks of open repair performed at a time when the patients are older and less fit for a major invasive procedure.
In the future, we hope to be able to individualize the threshold for intervention in patients with AAA on the basis of the risk of rupture, operative morbidity and mortality, life expectancy, and the durability of repair. Aneurysm diameter is likely to be a critical variable in weighing the relative importance of all four factors. In addition to PIVOTAL, the European-based 17-site Comparison of Surveillance vs Aortic Endografting for Small Aneurysm Repair (CAESAR) trial seeks to enroll 740 patients with AAA between 4 and 5.5 cm in diameter, randomizing between surveillance and EVAR with the Zenith device (Cook, Bloomington, Ind). 22 We anticipate substantial guidance toward that end will be gained when the PIVOTAL and CAESAR trials are complete, for the first time providing objective data on which to base clinical decisions in patients with small infrarenal AAAs.
